The overall aim of this trial is to determine the most cost effective approach to diagnose paroxysmal atrial fibrillation (PAF) following transient ischemic attack (TIA) and stroke. A summary of the rationale for this study is as follows: 1. Recently completed randomized trials of cardiac monitoring following stroke have established that PAF is more common than previously recognized in cryptogenic stroke. 2. The majority of TIA/stroke patients will have at least one potential stroke mechanism identified by the time etiologic investigations completed. 3. Detecting PAF in patients with strokes with known causes (eg. lacunar and large vessel atherosclerosis) is clinically important since appropriate anticoagulation for AF reduces stroke recurrence in all patients with prior TIA/stroke not just cryptogenic strokes. 4. There are competing technologies for evaluating cardiac rhythm and diagnosing AF but no cost effectiveness data 5. The rates of PAF in strokes with known causes (SKC) have not been well characterized. PER-DIEM is a pilot study to compare two different cardiac monitoring technologies as first-line investigations to detect PAF in patients with recent stroke and TIA. The study will also assess whether a pivotal trial is feasible and warranted. The principal research questions to be addressed in this study will be: 1. Whether implantable loop recorder (ILR) plus remote monitoring will diagnose more paroxysmal AF / atrial flutter and provide a better assessment of the total burden of AF resulting in a greater proportion of patients started on an OAC versus the external loop recorder (ELR) strategy. 2. What is the relative cost-effectiveness as a first-line investigation of long-term implantable ECG (ILR) coupled with remote monitoring for 12 months compared to external event-triggered ECG loop recorder (ELR) for 30 days in the diagnosis clinically actionable AF in following TIA/stroke. 2\) What is the feasibility, patient compliance, diagnostic accuracy and rates of AF detection (\>30 seconds) of ILR compared to the ELR strategies.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
300
Foothills Medical Centre
Calgary, Alberta, Canada
University of Alberta Hospital
Edmonton, Alberta, Canada
Grey Nuns Community Hospital
Edmonton, Alberta, Canada
Definite AF or Highly Probable AF
Definite AF or highly probable AF (adjudicated new AF lasting ≥2 minutes within 12 months of randomization)
Time frame: 12 months
AF Lasting ≥2 Min or Death by 12 Months
Detection of atrial fibrillation lasting ≥ 2 minutes or death by 12 months.
Time frame: 12 months
TIA
Transient ischemic attack.
Time frame: 12 months
Recurrent Stroke
Recurrent ischemic stroke.
Time frame: 12 months
Hemorrhage
Intracerebral hemorrhage.
Time frame: 12 months
Death
Participant death.
Time frame: 12 months
Oral Anticoagulation Therapy
Initiation of oral anticoagulation therapy in patients with definite AF.
Time frame: 12 months
≥1 Serious Adverse Event
Patients with ≥1 serious adverse event.
Time frame: 12 months
Compliance
Compliance with assigned therapy (accept ILR, conduct at least 80% of ELR assessments)
Time frame: 12 months
Costs of Cardiac and Non-cardiac Investigations
Costs for all cardiac and non-cardiac investigations related to etiologic workup of index stroke / TIA.
Time frame: 12 months
Duration of Any Detected Atrial Fibrillation / Atrial Flutter.
Total duration of any detected atrial fibrillation / atrial flutter.
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.